Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Kane Biotech Inc. (OTCQB:KNBIF) announced leadership changes, with Mark Nawacki becoming Chairman of the Board, while Philip Renaud transitions to Vice Chair. Renaud, the outgoing Chairman, emphasized the need for experienced leadership as the company approaches crucial advancements in Wound Care. Nawacki, with a background in pharmaceutical commercialization, expressed gratitude to Renaud and committed to guiding Kane Biotech's growth. The company specializes in technologies that combat microbial biofilms and holds 52 patents, indicating its strong research foundation.
Kane Biotech Inc. announces that Kevin Cole will be the new President and CEO of STEM Animal Health Inc., its subsidiary formed through a joint venture with Animalcare Group PLC. Cole has extensive experience in the pet care industry, previously serving as President of True Leaf Pet. His focus will be on expanding STEM's reach in the $150 billion global pet care market, intent on leveraging the company's innovative biofilm-targeting technology. Additionally, a new Board of Directors has been established to support STEM, with Kane Biotech’s CEO Marc Edwards as Chairman.